Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

FDA Sets Action Date for Review of CTI’s Pixantrone NDA

By Pharmaceutical Processing | September 8, 2009

Cell Therapeutics, Inc. has announced that the FDA has notified CTI that a Prescription Drug User Fee Act(PDUFA) action date of April 23, 2010 under standard review has beenestablished regarding CTI’s NDA for pixantrone as potential treatment forrelapsed or refractory aggressive non-Hodgkin’s lymphoma (NHL). Pixantrone hasfast track designation for the relapsed / refractory aggressive NHLapplication. “The 18 month follow up PIX 301 pivotal trial data continues todemonstrate further improvement in primary and secondary endpoints includingComplete Remission / Complete Remission unconfirmed(CR/CRu), Progression FreeSurvival (PFS) and Overall Survival over standard chemotherapy. We lookforward to providing the four month safety and efficacy update to the FDA andworking with them toward potential approval,” said James A. Bianco, M.D.,Chief Executive Officer of CTI. Based on the user fee goal date, if pixantrone is approved, CTI estimatesthat pixantrone could be available to patients in the U.S. early in the secondquarter of 2010.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE